A Meta-Analysis of Clinical Advancement in Sanfilippo Syndrome Type A

Kassidi S. Petersen  
*Boise State University*

Molly Ross  
*Boise State University*

Molly Felix  
*Boise State University*

Lauren Grillo  
*Boise State University*

Cassandra Marshall  
*Boise State University*

*See next page for additional authors*
INTRODUCTION

Background information about the disease
Sanfilippo syndrome (also known as MPSIII) type A is caused by the mutation of the gene encoding SGSH, N-sulfoglucosamine sulfohydrolase, on chromosome 17, region 17q25.3

- It is a recessive gene that affects around 1 in 70,000 babies each year
- This mutation affects the mucopolysaccharides and causes the patient to lose an enzyme that is crucial to breaking down heparan sulfate
  - Heparan sulfate is stored in the cells instead of breaking down and causes progressive damage
- Symptoms become apparent after the age of 1-year-olds
  - Learning abilities decline after the ages of 2 and 6
  - Limit of physical growth, resulting in small stature
  - Other common symptoms include:
    - Behavioral problems
    - Coarse facial features
    - Full lips
    - Difficult walking
- Diagnosis includes a urine test looking for high levels of mucopolysaccharides

PROSPECTIVE TREATMENT

Enzyme Replacement Therapy and Outcomes
Enzyme replacement therapy has gone through multiple trials to see if testing different ways to replace the missing enzyme that inhibits the degradation of MPS.

- Animal models of enzyme therapy
  - Protein fusion and direct administration to CNS have been proven effective.
  - Problems are a high concentration of enzymes are needed and fusion to CNS is highly invasive and may not work on children, the main affected population
- Clinical enzyme replacement trials
  - Began in 2016 with 12 patients
  - In the trial recombinant human heparan-N-Sulfatase has been administered intrathecally to each of the patients monthly
  - 4 showed a decline in development 6 remained stable and 2 were inconclusive

Gene therapy in Sanfilippo Syndrome Type A is used in hopes that the stem cells that are introduced from the bone marrow of a healthy individual will be catalytically active and this activity will spread to native cells so that they will be catalytically active too.

- Preliminary testing in mice showed significant decrease in activity after treatment if treated early.
  - Mice treated with a Sulfate Modifying Factor 1 in the SGSH gene using an internal ribosomal entry site (SGSH-ires-SUMF1) showed activity similar to normal mice. Early treatment by injection was sufficient in prevention or delay of central nervous system issues in mice with Sanfilippo Syndrome. This study and others like it allowed human clinical trials to begin. (Fraldi A, et al.)
- In human trials, a similar result was found. The best outcomes are from younger patients who received treatment early. During the trials, patients showed no negative side effects at the
  - Injection site. (Tardieu M, et al.)
- Treatment for this disease using stem cells in bone marrow is still in trials but looks hopeful.

CONCLUSION

Overall, treatments for Sanfilippo Syndrome type A are still in the preliminary stages. Enzyme replacement therapy and gene therapy currently are at the forefront of research. The advancement of clinical trials to human subjects will be of principal interest as research continues. MPS III is a syndrome associated with high lethality; it is crucial that therapies are effective for young individuals. Due to this, our meta-analysis found gene therapy to be a more promising avenue of treatment. Future research should heavily invest in gene therapy to improve outcomes for affected individuals.

Psychological and Cultural Considerations

Psychological Symptom Management:
Sanfilippo syndrome presents initially with psychosomatic symptoms, similar to those seen in individuals with ADHD. Research into management of these symptoms is critical to patient wellbeing as well as elevating quality of life.

Cultural Considerations:
Attention to areas of prevalence should also be taken into account with this syndrome. Geographic distribution of Sanfilippo shows the highest density of cases in Australia. Distribution data outside of Europe and Australia is lacking. It is highly possible that cases are under reported in developing countries.

Citations

